Skip to content

Study · Observational study · n = 87 · 2022

5 results

Effect of Cerebrolysin in severe traumatic brain injury: A multi-center, retrospective cohort study.

Lucena LLN, Briones MVA

Clinical neurology and neurosurgery23 Mar 2022Cited by 7 (Europe PMC)

PMID35344761 (opens in a new tab)DOI10.1016/j.clineuro.2022.107216 (opens in a new tab)PepBankPUB-35344761
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In nonoperative severe TBI patients, Cerebrolysin was linked to a higher favourable-outcome proportion than standard decompression alone.

    In plain wordsIn severe TBI patients, Cerebrolysin was linked to more favourable outcomes than standard decompression alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFavourable outcome at Day 21
    Study

    n = 87

    Comparator
    Standard decompression protocol only
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml/day for 14 days, then 10 ml/day for another 14 days · 14 days followed by another 14 daysAs given in this study (human).

    Measurements

    Favourable outcome at Day 21 post-TBI proportion
    50%
    first reported percentage in Cerebrolysin versus control comparison; arm order not explicit
    Favourable outcome at Day 21 post-TBI proportion
    87%
    second reported percentage in Cerebrolysin versus control comparison; arm order not explicit
    p value for Favourable outcome at Day 21 post-TBI
    < 0.00001
    Cerebrolysin versus standard decompression control

    Source sentences

    Summary
    Compared to the control group, a significantly higher proportion of patients who received Cerebrolysin treatment achieved a favourable outcome at Day 21 post-TBI (50% vs. 87%; p < 0.00001) and GOS ≥ 4 (18% vs. 39%; p = 0.043).
    3 context sentences
    Summary · context
    The study employed a retrospective cohort design and included 87 severe TBI patients on admission.
    Summary · context
    In addition to the current medical decompression protocol, 42 patients received 30 ml/day Cerebrolysin for 14 days, followed by a subsequent 10 ml/day dosage for another 14 days.
    Summary · context
    The control group included 45 patients who received the standard decompression protocol only.
  2. 02HumanObservational studyEfficacy outcome

    In nonoperative severe TBI patients, Cerebrolysin was linked to a higher proportion with GOS ≥ 4 than standard decompression alone.

    In plain wordsIn severe TBI patients, Cerebrolysin was linked to more favourable GOS scores than standard decompression alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGOS ≥ 4
    Study

    n = 87

    Comparator
    Standard decompression protocol only
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml/day for 14 days, then 10 ml/day for another 14 days · 14 days followed by another 14 daysAs given in this study (human).

    Measurements

    GOS ≥ 4 proportion
    18%
    first reported percentage in Cerebrolysin versus control comparison; arm order not explicit
    GOS ≥ 4 proportion
    39%
    second reported percentage in Cerebrolysin versus control comparison; arm order not explicit
    p value for GOS ≥ 4
    0.043
    Cerebrolysin versus standard decompression control

    Source sentences

    Summary
    Compared to the control group, a significantly higher proportion of patients who received Cerebrolysin treatment achieved a favourable outcome at Day 21 post-TBI (50% vs. 87%; p < 0.00001) and GOS ≥ 4 (18% vs. 39%; p = 0.043).
    3 context sentences
    Summary · context
    The study employed a retrospective cohort design and included 87 severe TBI patients on admission.
    Summary · context
    In addition to the current medical decompression protocol, 42 patients received 30 ml/day Cerebrolysin for 14 days, followed by a subsequent 10 ml/day dosage for another 14 days.
    Summary · context
    The control group included 45 patients who received the standard decompression protocol only.
  3. 03HumanObservational studyEfficacy outcome

    In severe TBI patients, Cerebrolysin was linked to shorter hospital stay than standard decompression alone, 25.61 versus 31.92 days.

    In plain wordsIn severe TBI patients, Cerebrolysin was linked to shorter hospital stays than standard decompression alone.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseHospital stay length
    Study

    n = 87

    Comparator
    Standard decompression protocol only
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    30 ml/day for 14 days, then 10 ml/day for another 14 days · 14 days followed by another 14 daysAs given in this study (human).

    Measurements

    Mean length of hospital stay
    25.61 days
    Cerebrolysin
    Mean length of hospital stay
    31.92 days
    Control
    Mean hospital stay reduction
    ≈ 7 days
    Cerebrolysin versus standard decompression control
    p value for mean hospital stay
    < 0.00001
    Cerebrolysin versus standard decompression control

    Source sentences

    Summary
    The mean length of hospital stay was approximately seven days shorter in the Cerebrolysin group (25.61 days vs. 31.92 days; p < 0.00001)
    3 context sentences
    Summary · context
    The study employed a retrospective cohort design and included 87 severe TBI patients on admission.
    Summary · context
    In addition to the current medical decompression protocol, 42 patients received 30 ml/day Cerebrolysin for 14 days, followed by a subsequent 10 ml/day dosage for another 14 days.
    Summary · context
    The control group included 45 patients who received the standard decompression protocol only.
  4. 04HumanObservational studyEfficacy outcome

    In severe TBI patients, LOS ≥ 30 days occurred in 13% with Cerebrolysin versus 51% with standard decompression alone.

    In plain wordsIn severe TBI patients, Cerebrolysin was linked to fewer prolonged hospital stays than standard decompression alone.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseLOS ≥ 30 days
    Study

    n = 87

    Comparator
    Standard decompression protocol only
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    30 ml/day for 14 days, then 10 ml/day for another 14 days · 14 days followed by another 14 daysAs given in this study (human).

    Measurements

    Proportion with length of stay >= 30 days
    13%
    Cerebrolysin
    Proportion with length of stay >= 30 days
    51%
    Control
    p value for proportion with LOS ≥ 30 days
    < 0.0001
    Cerebrolysin versus standard decompression control

    Source sentences

    Summary
    and a significantly lower proportion of Cerebrolysin patients had a LOS ≥ 30 days (Cerebrolysin: 13%; Control: 51%; p < 0.0001).
    3 context sentences
    Summary · context
    The study employed a retrospective cohort design and included 87 severe TBI patients on admission.
    Summary · context
    In addition to the current medical decompression protocol, 42 patients received 30 ml/day Cerebrolysin for 14 days, followed by a subsequent 10 ml/day dosage for another 14 days.
    Summary · context
    The control group included 45 patients who received the standard decompression protocol only.
  5. 05HumanObservational studySafety outcome

    In severe TBI patients, 28-day mortality did not differ significantly between Cerebrolysin and standard decompression alone.

    In plain wordsIn severe TBI patients, mortality did not differ significantly between Cerebrolysin and standard decompression alone.

    Peptide
    Cerebrolysin
    Outcome
    No significant change28-day mortality
    Study

    n = 87

    Comparator
    Standard decompression protocol only
    Outcome group
    Mortality · Whole body
    Studied dose
    30 ml/day for 14 days, then 10 ml/day for another 14 days · 14 days followed by another 14 daysAs given in this study (human).

    Source sentences

    Summary
    No significant group differences were seen in the 28-day mortality rate.
    3 context sentences
    Summary · context
    The study employed a retrospective cohort design and included 87 severe TBI patients on admission.
    Summary · context
    In addition to the current medical decompression protocol, 42 patients received 30 ml/day Cerebrolysin for 14 days, followed by a subsequent 10 ml/day dosage for another 14 days.
    Summary · context
    The control group included 45 patients who received the standard decompression protocol only.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.